Scientists link another gene to degenerative blindness

January 18, 2006

Researchers have labored for decades to understand blindness-inducing neurodegenerative diseases such as age-related macular degeneration (AMD) and retinitis pigmentosa (RP).

It has been a painstaking scientific journey as AMD and RP each belong to a complex family of disorders, in which every disorder has many forms and each form is encoded with a distinct genetic recipe. Even AMD, a major cause of vision loss in people over 60, is actually a collection of more than 50 diseases.

Now, a team of researchers at the University of Wisconsin-Madison has taken a small but crucial step forward in the ongoing fight against retinal degeneration. Working with fruit flies, the scientists have discovered that a mutation in a common gene called calnexin can derail the light-processing activity of cells and set in motion the gradual breakdown of vision. They report their findings today in the journal Neuron.

Calnexin-found in both fruit flies and humans-functions as a cellular chaperone, ensuring that proteins "fold" or orient properly and get to the parts of the cell they need to go. It also modulates calcium levels, which is critical for proper vision.

When calnexin goes awry, however, calcium levels build up and the proteins that depend on it malfunction, says senior author Nansi Jo Colley, a medical geneticist at the UW-Madison departments of ophthalmology and genetics, and an affiliate of the Eye Research Institute.

At a time when more than 103 genes are known to be involved with AMD and RP, the UW-Madison work could one day help doctors deliver tailor-made treatments to patients who specifically carry calnexin mutations. Because the calnexin protein and other chaperones are also present in the brain, the work can help to answer broader questions about neurodegenerative disease, Colley adds.

"Understanding the basic mechanisms of how proteins are folded holds the key to finding treatments for not only retinal degenerative diseases but also other neurodegenerative diseases such as Alzheimer's, Huntington's and Parkinson's."

To detect the calnexin mutation, the UW-Madison team used genetic mapping to zero in on the exact region harboring the mutant. Subsequent DNA sequencing of that target area pinpointed calnexin as the culprit gene, explains lead author Erica Rosenbaum, a researcher in Colley's laboratory.

Colley plans to continue searching for other genetic mutations that might help trigger retinal degeneration. "The more mutations we identify the easier it will be to step back and look at the big picture of the general principles of neurodegeneration," she says.
-end-
Paroma Basu, (608) 262-9772, basu1@wisc.edu
Nansi Jo Colley, (608) 265-5398, njcolley@wisc.edu

University of Wisconsin-Madison

Related Neurodegenerative Diseases Articles from Brightsurf:

Bringing drugs to the brain with nanoparticles to treat neurodegenerative diseases
Researchers from the Institut national de la recherche scientifique (INRS) have shown that nanoparticles could be used to deliver drugs to the brain to treat neurodegenerative diseases.

First 'pathoconnectome' could point toward new treatments for neurodegenerative diseases
Scientists from the John A. Moran Eye Center at the University of Utah have achieved another first in the field of connectomics, which studies the synaptic connections between neurons.

Unlocking the mystery of tau for treatment of neurodegenerative diseases
A team of researchers from various collaborating universities and hospitals in Japan has uncovered crucial molecular details regarding the activity of the ''tau'' protein, promising to revolutionize the therapy of tau-induced neurodegenerative diseases.

Investigational drug stops toxic proteins tied to neurodegenerative diseases
An investigational drug that targets an instigator of the TDP-43 protein, a well-known hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), may reduce the protein's buildup and neurological decline associated with these disorders, suggests a pre-clinical study from researchers at Penn Medicine and Mayo Clinic.

Inhibition of sphingolipid metabolism and neurodegenerative diseases
Disrupting the production of a class of lipids known as sphingolipids in neurons improved symptoms of neurodegeneration and increased survival in a mouse model.

How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases
How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases

New family of molecules to join altered receptors in neurodegenerative diseases
An article published in the Journal of Medicinal Chemistry shows a new family of molecules with high affinity to join imidazoline receptors, which are altered in the brain of those patients with neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's.

Examining diagnoses of stress-related disorders, risk of neurodegenerative diseases
Researchers investigated how stress-related disorders (such as posttraumatic stress disorder, adjustment disorder and stress reactions) were associated with risk for neurodegenerative diseases, including Alzheimer and Parkinson disease and amyotrophic lateral sclerosis (ALS), using data from national health registers in Sweden.

Toxic protein, linked to Alzheimer's and neurodegenerative diseases, exposed in new detail
The protein tau has long been implicated in Alzheimer's and a host of other debilitating brain diseases.

Study uncovers unexpected connection between gliomas, neurodegenerative diseases
New basic science and clinical research identifies TAU, the same protein studied in the development of Alzheimer's, as a biomarker for glioma development.

Read More: Neurodegenerative Diseases News and Neurodegenerative Diseases Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.